# A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

> **NCT01526369** · PHASE3 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 75 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT01526369
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-13
- **Primary completion:** 2015-11
- **Final completion:** 2023-02-17
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526369, "A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01526369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*